Literature DB >> 28247763

N,N-Dimethyl Tertiary Amino Group Mediated Dual Pancreas- and Lung-Targeting Therapy against Acute Pancreatitis.

Shi Luo1, Peiwen Li1, Sha Li1, Zhengwu Du1, Xun Hu1, Yao Fu1, Zhirong Zhang1.   

Abstract

Acute pancreatitis (AP) is a sudden inflammation of the pancreas with high mortality rate worldwide. As a severe complication to AP, acute lung injury has been the major cause of death among patients with AP. Poor penetration across the blood pancreas barrier (BPB) and insufficient drug accumulation at the target site often result in poor therapeutic outcome. Our previous work successfully demonstrated a dual-specific targeting strategy to pancreas and lung using a phenolic propanediamine moiety. Inspired by this, a simplified ligand structure, N,N-dimethyl tertiary amino group, was covalently conjugated to celastrol (CLT) to afford tertiary amino conjugates via either an ester (CP) or an amide linkage (CTA). With sufficient plasma stability, CTA was subjected to the following studies. Compared to CLT, CTA exhibited excellent cellular uptake efficiency in both rat pancreatic acinar cell line (AR42J) and human pulmonary alveolar epithelial cell line (A549). Organic cation transporters were proven to be responsible for this active transport process. Given systemically, CTA specifically distributed to pancreases and lungs in rats thus resulting in a 2.59-fold and 3.31-fold increase in tissue-specific accumulation as compared to CLT. After CTA treatment, tissue lesions were greatly alleviated and the levels of proinflammatory cytokines were downregulated in rats with sodium taurocholate induced AP. Furthermore, CTA demonstrated marginal adverse effect against major organs with reduced cardiac toxicity compared to CLT. Together, tertiary amine mediated dual pancreas- and lung-targeting therapy represents an efficient and safe strategy for AP management.

Entities:  

Keywords:  acute pancreatitis; anti-inflammatory; celastrol; dual-specific targeting; tertiary amine

Mesh:

Substances:

Year:  2017        PMID: 28247763     DOI: 10.1021/acs.molpharmaceut.7b00028

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  5 in total

1.  A novel gemcitabine derivative-loaded liposome with great pancreas-targeting ability.

Authors:  Pei-Wen Li; Shi Luo; Lin-Yu Xiao; Bo-le Tian; Li Wang; Zhi-Rong Zhang; Ying-Chun Zeng
Journal:  Acta Pharmacol Sin       Date:  2019-04-23       Impact factor: 6.150

2.  Neutrophil-mimicking therapeutic nanoparticles for targeted chemotherapy of pancreatic carcinoma.

Authors:  Xi Cao; Ying Hu; Shi Luo; Yuejing Wang; Tao Gong; Xun Sun; Yao Fu; Zhirong Zhang
Journal:  Acta Pharm Sin B       Date:  2018-12-26       Impact factor: 11.413

Review 3.  From Marine Metabolites to the Drugs of the Future: Squalamine, Trodusquemine, Their Steroid and Triterpene Analogues.

Authors:  Oxana Kazakova; Gulnara Giniyatullina; Denis Babkov; Zdenek Wimmer
Journal:  Int J Mol Sci       Date:  2022-01-19       Impact factor: 5.923

4.  Enhancement of Antitumor Efficacy of Paclitaxel-Loaded PEGylated Liposomes by N,N-Dimethyl Tertiary Amino Moiety in Pancreatic Cancer.

Authors:  Yang Chen; Li Wang; Shi Luo; Jun Hu; Xing Huang; Pei-Wen Li; Yi Zhang; Chao Wu; Bo-Le Tian
Journal:  Drug Des Devel Ther       Date:  2020-07-23       Impact factor: 4.162

5.  Drug discovery and formulation development for acute pancreatitis.

Authors:  Xue Jiang; Ya-Wen Zheng; Shihui Bao; Hailin Zhang; Ruijie Chen; Qing Yao; Longfa Kou
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.